Somewhat Late To The HCV Race, Novartis Licenses NS5A Inhibitor From Enanta
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase I-ready compound joins alisporivir, a cyclophilin inhibitor licensed from Debiopharm in 2010, in Novartis’ rather slight portfolio of HCV candidates.
You may also be interested in...
Deal Watch: Tax Policy Changes Claiming Victims Already, As Salix/Cosmo Plans Abandoned
Abandoned deals were the order of the week as the Salix/Cosmo breakup followed Novartis’ exit from hepatitis C drug development and a partnership in that space with Enanta. J&J, however, increased its bet on HCV by acquiring Alios, one of several noteworthy buyouts occurring during the week.
IPOs: Enanta Wows While Tetraphase Gets The Job Done
A pair of biotech IPOs priced on March 20 with mixed results. Hepatitis C developer Enanta got a warm reception from investors looking to tap into what has been a lucrative sector. But antibiotics company Tetraphase priced below its range and traded flat.
Novartis And Idenix Break Up
Novartis and Idenix have all but ended the co-development and commercialization agreement that was established in 2003 and gave Novartis a controlling option in the company.